Lee:JC

Home        Research        Lab Members        Publications        Transporters        Proteasomes        PK/PD/PGx        JC        Links        Internal        Contact       

• Cancer JC: click for the schedule

9 am, every monday, COP Rm 442

Suggested future papers

1. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, and Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009 Jul;15(7):781-7. DOI:10.1038/nm.1978 |
2. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 |
3. Kotamraju S, Matalon S, Matsunaga T, Shang T, Hickman-Davis JM, and Kalyanaraman B. Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med. 2006 Mar 15;40(6):1034-44. DOI:10.1016/j.freeradbiomed.2005.10.052 |

Past papers

2009

1. Fang C, Dean J, and Smith JW. A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-kappaB activation in colorectal adenocarcinoma. Cancer Res. 2007 Oct 1;67(19):9039-46. DOI:10.1158/0008-5472.CAN-06-3690 |
2. Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, and Ping P. Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics. 2009 Feb;8(2):302-15. DOI:10.1074/mcp.M800058-MCP200 |
3. Gui C and Hagenbuch B. Amino acid residues in transmembrane domain 10 of organic anion transporting polypeptide 1B3 are critical for cholecystokinin octapeptide transport. Biochemistry. 2008 Sep 2;47(35):9090-7. DOI:10.1021/bi8008455 |
4. Iorns E, Lord CJ, and Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009 Jan 1;417(1):361-70. DOI:10.1042/BJ20081682 |
5. Inoue S, Nakase H, Matsuura M, Mikami S, Ueno S, Uza N, and Chiba T. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol. 2009 Apr;156(1):172-82. DOI:10.1111/j.1365-2249.2008.03872.x |
6. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindström MS, Bhat KP, Godfrey VL, Evan GI, and Zhang Y. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007 Oct;12(4):355-66. DOI:10.1016/j.ccr.2007.09.007 |
7. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z, Cohen L, Danon T, Perzov N, and Alon U. Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008 Dec 5;322(5907):1511-6. DOI:10.1126/science.1160165 |
8. Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, and Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000 Apr 15;60(8):2090-4.
9. Cohen L, Henzel WJ, and Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):292-6. DOI:10.1038/26254 |
10. Rothwarf DM, Zandi E, Natoli G, and Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998 Sep 17;395(6699):297-300. DOI:10.1038/26261 |
11. Kravtsova-Ivantsiv Y, Cohen S, and Ciechanover A. Modification by single ubiquitin moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 NF-kappaB precursor. Mol Cell. 2009 Feb 27;33(4):496-504. DOI:10.1016/j.molcel.2009.01.023 |
12. Shah K, Liu Y, Deirmengian C, and Shokat KM. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70. DOI:10.1073/pnas.94.8.3565 |
13. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, and Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007 Feb;11(2):119-32. DOI:10.1016/j.ccr.2006.12.016 |
14. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, and Schreiber SL. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature. 1998 Oct 29;395(6705):917-21. DOI:10.1038/27699 |
15. Yang Z, Gagarin D, St Laurent G 3rd, Hammell N, Toma I, Hu CA, Iwasa A, and McCaffrey TA. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1213-9. DOI:10.1161/ATVBAHA.109.189407 |
16. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004 Sep 23;431(7007):461-6. DOI:10.1038/nature02924 |
17. Wang YD, Chen WD, Wang M, Yu D, Forman BM, and Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology. 2008 Nov;48(5):1632-43. DOI:10.1002/hep.22519 |
18. Nakagawa H, Tamura A, Wakabayashi K, Hoshijima K, Komada M, Yoshida T, Kometani S, Matsubara T, Mikuriya K, and Ishikawa T. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem J. 2008 May 1;411(3):623-31. DOI:10.1042/BJ20071229 |
19. Kimura Y, Yashiroda H, Kudo T, Koitabashi S, Murata S, Kakizuka A, and Tanaka K. An inhibitor of a deubiquitinating enzyme regulates ubiquitin homeostasis. Cell. 2009 May 1;137(3):549-59. DOI:10.1016/j.cell.2009.02.028 |